{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:20:35Z","timestamp":1793780435393,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.esmoop.2023.102065","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T16:52:22Z","timestamp":1700499142000},"page":"102065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-4454","authenticated-orcid":false,"given":"H.","family":"Borghaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-E.","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pluzanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nagrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Havel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Kowalyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ntambwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Rabindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.E.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Balli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2023.102065_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102065_bib2","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102065_bib3","doi-asserted-by":"crossref","first-page":"P204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2023.102065_bib4","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2023.102065_bib5","first-page":"S448","article-title":"KEYNOTE-189 5-year update: first-line pembrolizumab (pembro)\u00a0+ pemetrexed (pem) and platinum vs placebo (pbo)\u00a0+ pem and platinum for metastatic nonsquamous NSCLC","volume":"33","author":"Garassino","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.102065_bib6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer: 5 year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102065_bib7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102065_bib8","doi-asserted-by":"crossref","first-page":"S1792","DOI":"10.1016\/j.jtho.2017.09.429","article-title":"First-line nivolumab plus platinum-based doublet chemotherapy for advanced NSCLC: CheckMate 012 3-year update","volume":"12","author":"Juergens","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2023.102065_bib9","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102065_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102065_bib11","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2023.102065_bib12","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2023.102065_bib13","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102065_bib14","unstructured":"Opdivo\u00ae (nivolumab) [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2023. Available at https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed March 8, 2023."},{"issue":"9","key":"10.1016\/j.esmoop.2023.102065_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2023.102065_bib18","doi-asserted-by":"crossref","first-page":"CT082","DOI":"10.1158\/1538-7445.AM2017-CT082","article-title":"Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026","volume":"77","author":"Peters","year":"2017","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2023.102065_bib19","doi-asserted-by":"crossref","first-page":"S750","DOI":"10.1016\/S1556-0864(21)01940-7","article-title":"98O First-line nivolumab (NIVO)+ ipilimumab (IPI)+ 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA","volume":"16","author":"Paz-Ares","year":"2021","journal-title":"J\u00a0Thoracic Oncol"},{"key":"10.1016\/j.esmoop.2023.102065_bib20","article-title":"Evaluation of the Lung Immune Prognostic Index in non-small cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.102065_bib21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102065_bib22","first-page":"162","article-title":"The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors","volume":"64","author":"Benitez","year":"2020","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.esmoop.2023.102065_bib23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers13051176","article-title":"Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the IMPOWER150 trial","volume":"13","author":"Hopkins","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102065_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2023.102065_bib26","doi-asserted-by":"crossref","first-page":"CT078","DOI":"10.1158\/1538-7445.AM2018-CT078","article-title":"Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo)\u00a0+ ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568","volume":"78","author":"Ramalingam","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2023.102065_bib27","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2023.102065_bib28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.102065_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2023.102065_bib30","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"16","author":"Lang","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.102065_bib31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A\u00a0randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2023.102065_bib32","first-page":"S1373","article-title":"Nivolumab (NIVO)\u00a0+ ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 Part 1: efficacy by KRAS, STK11, and KEAP1 mutation status","volume":"32","author":"Ramalingam","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.102065_bib33","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC","volume":"4","author":"Garassino","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2023.102065_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/diagnostics12020423","article-title":"Prognostic nutritional index and lung immune prognostic index as prognostic predictors for combination therapies of immune checkpoint inhibitors and cytotoxic anticancer chemotherapy for patients with advanced non-small cell lung cancer","volume":"12","author":"Tanaka","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"15","key":"10.1016\/j.esmoop.2023.102065_bib35","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cancers13153776","article-title":"Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors","volume":"13","author":"Auclin","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2023.102065_bib36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.21037\/tlcr.2019.11.07","article-title":"Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy","volume":"8","author":"Ruiz-Ba\u00f1obre","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"22","key":"10.1016\/j.esmoop.2023.102065_bib37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.21037\/atm-21-1702","article-title":"Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1\/PD-L1 therapy","volume":"9","author":"Ali","year":"2021","journal-title":"Ann Transl Med"},{"issue":"24","key":"10.1016\/j.esmoop.2023.102065_bib38","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.esmoop.2023.102065_bib41","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2023.102065_bib42","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923013066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923013066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:34:21Z","timestamp":1761856461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923013066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2059702923013066"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102065","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102065"}}